GlassScriptPhysician profile
Ilene April Stone
NPI 1275569253
$846.51
in general payments reported to CMS, 2019-2025
20 companies · $788 in 2025
The $788 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $58.96 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $240.48 | 2025 | Bimzelx, Rystiggo, Zilbrysq |
| Astellas Pharma US INC | $90.50 | 2025 | Veozah |
| Novo Nordisk INC | $73.64 | 2025 | Wegovy |
| Abbvie INC. | $57.53 | 2025 | |
| Lilly USA, LLC | $40.71 | 2025 | Zepbound, Mounjaro |
| Genzyme Corporation | $32.74 | 2025 | |
| Pfizer INC. | $31.82 | 2025 | |
| Vanda Pharmaceuticals INC. | $30.93 | 2025 | Ponvory |
| Lundbeck LLC | $30.61 | 2025 | Vyepti |
| Madrigal Pharmaceuticals | $26.05 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $24.73 | 2025 | Nexletol |
| Genentech USA, INC. | $23.27 | 2025 | Evrysdi |
| Ge Healthcare | $22.00 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.65 | 2024 | Caplyta |
| Merck Sharp & Dohme LLC | $19.98 | 2024 | Capvaxive, Gardasil 9, Gardasil |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.00 | 2025 | Orencia |
| Biogen, INC. | $18.33 | 2024 | Leqembi |
| Exact Sciences Corporation | $14.95 | 2025 | Cologuard Collection Kit |
| Sequel Med Tech, LLC | $14.78 | 2025 | Twiist |
| Amgen INC. | $13.81 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilene Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.